Project Grant R01HL178857
Award Date 8/1/25
Completion Date 5/31/29
Dollars Obligated $761K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $540,856 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The Regents of the University of California, San Francisco (UCSF) on Dec 15, 2024. The goal of this 4-year project is to identify transcriptional regulators that control endocardial-specific gene expression and valve development, as well as understand the regulation and function of the SLC16A2 gene during heart injury and regeneration. The...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $126,306 Project Grant under CFDA 93.837 - Cardiovascular Diseases Research to the University of Washington. The goal of this 2-year award is to establish a system to accelerate the reclassification of variants of unknown significance in the MYH7 gene, which cause hypertrophic cardiomyopathy, and determine the role of genetic modifiers that influence the severity of this disease. The research will utilize human induced pluripotent...
- The University of California, San Diego (UCSD) was awarded a $788,513 project grant by the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to study the mechanisms underlying the maintenance of cardiac chamber identity in zebrafish. The research aims to elucidate the genetic pathways that reinforce ventricular cardiomyocyte identity, as ventricular myocardium harbors considerable plasticity and can transform to acquire atrial traits under certain...
- This Project Grant award for $727,710.00 from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) aims to advance understanding of the mechanisms driving arrhythmogenic cardiomyopathy, a genetic heart disease that can cause sudden death in young people. The award supports research at the University of California, San Diego (UCSD) to develop preclinical mouse models exhibiting inflammation and T-cell mediated immune responses as key drivers of this...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $811,885 in funding to the J. David Gladstone Institutes in California to conduct research on epigenomic mechanisms of cardiac fibrosis and heart failure. The project aims to investigate the role of the MEOX1 gene as a key transcriptional regulator of fibroblast activation, fibrosis, and heart failure pathogenesis. The research leverages novel genetic mouse...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $243,000 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of Cincinnati's Sponsored Research Services Division. The grant will fund a 2-year project to engineer advanced RNA biodevices that leverage CRISPR and ADAR gene-editing technologies. The goal is to improve the efficiency and specificity of converting resident cardiac fibroblasts into functional cardiomyocytes, in order to boost...
- The University of California, Davis received a $400,417 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) to conduct research on cardiac regenerative therapy using gene-edited stem cells. The goal is to improve transplantation outcomes and address the critical role of inflammation-induced cell death that impedes current cardiac stem cell therapies. The research aims to develop new treatments for end-stage heart failure, a...
- This $713,511 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research into the impact of myosin-binding protein C (MyBP-C) on myosin mobility and proteostasis in the context of hypertrophic cardiomyopathy (HCM). The University of Vermont & State Agricultural College, the awardee, will utilize innovative techniques to investigate how reduced MyBP-C levels, a common cause of HCM, may disrupt normal heart...
- This federal Project Grant award, valued at $765,288.00, was provided by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837). The funding supports research at the University of California, San Diego (UCSD) to investigate the biological mechanisms of the infarct borderzone - the complex and dynamic region between areas of cell death and normal tissue in the heart following a myocardial infarction. The research aims to advance...
- This $125,703 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research investigating the role of the SYNE1-giant gene in atrial cardiomyopathy. The principal investigator is conducting a comprehensive study to understand the mechanisms by which mutations in the SYNE1 gene, which encodes mechanosensitive proteins in the nuclear envelope, contribute to the development of atrial fibrillation and sinus node dysfunction....